课题基金 / 基金详情

PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS

PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS
重组人 IL-12 在 HIV 感染者中的 I 期双盲试验
批准号：
6118452
负责人：
STEVEN MILES
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118452
关键词：
HIV infections cell type clinical research clinical trial phase I dosage drug administration routes drug screening /evaluation drug tolerance human subject human therapy evaluation immune system injection /infusion interleukin 12 microorganism disease chemotherapy pharmacokinetics recombinant proteins volunteer

项目摘要

项目成果

STEVEN MILES的其他基金

相似基金

相关文献

中文摘要
翻译
研究用药rhIL-12是一种实验药物，尚未获得美国食品和药物管理局(FDA)的批准。这项两部分研究的目的是确定几种剂量的重组人白细胞介素12的安全性和耐受性，该药将通过皮下注射给药。IL-12是一种蛋白质，由免疫系统的某些类型的细胞自然产生，被认为对免疫功能很重要。大约54名志愿者将参加这项为期十周的艾滋病毒感染者研究。虽然rh IL-12对HIV没有直接作用，但它可能会提高免疫系统对抗HIV病毒的能力。
英文摘要
The study medication, rhIL-12, is an experimental drug that hasn't been approved by the Food and Drug Administration (FDA). The purpose of this two-part study is to determine the safety and tolerance of several doses of rhIL-12, which will be given under the skin by injection. IL-12 is a type of protein that is naturally produced by certain types of cells of the immune system and is believe to be important for immune function. About 54 volunteers will take part in this ten-week study in HIV-infected people. Although rhIL-12 has no direct effect against HIV, rhIL-12 may improve the ability of the immune system to fight the HIV virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II TRIAL OF 9-CIS RETINOIC ACID (ALRT 1057) IN AIDS-KS (AMC PROT.002)
DOSE ESCALATING STUDY OF CUTANEOUS AIDS RELATED KAPOSI'S SARCOMA
STEM CELL MOBILIZATION AND HARVESTING FROM THE PERIPHERAL BLOOD
PHASE I,DOOUBLE-BLINDED TRIAL OF RECOMBINANT HUMAN IL-12 IN HIV INFECTED PTS
海外基金